Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

1.

Drug treatments to restore vascular function and diabesity.

Cardillo C.

Ann Pharm Fr. 2013 Jan;71(1):27-33. doi: 10.1016/j.pharma.2012.09.001. Epub 2012 Oct 1. Review.

PMID:
23348853
[PubMed - indexed for MEDLINE]
2.

Diabesity: therapeutic options.

Colagiuri S.

Diabetes Obes Metab. 2010 Jun;12(6):463-73. doi: 10.1111/j.1463-1326.2009.01182.x. Review.

PMID:
20518802
[PubMed - indexed for MEDLINE]
3.

Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.

Forst T, Weber MM, Pfützner A.

Exp Diabetes Res. 2012;2012:635472. doi: 10.1155/2012/635472. Epub 2012 Apr 17. Review.

PMID:
22577369
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Emerging therapies in the treatment of 'diabesity': beyond GLP-1.

Tharakan G, Tan T, Bloom S.

Trends Pharmacol Sci. 2011 Jan;32(1):8-15. doi: 10.1016/j.tips.2010.10.003. Epub 2010 Dec 3. Review.

PMID:
21130506
[PubMed - indexed for MEDLINE]
5.

Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.

Schnabel CA, Wintle M, Kolterman O.

Vasc Health Risk Manag. 2006;2(1):69-77. Review.

PMID:
17319471
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.

Otsuki M, Goya K, Kasayama S.

Vasc Health Risk Manag. 2005;1(3):209-15. Review.

PMID:
17319106
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay.

Niswender K.

Diabetes Obes Metab. 2010 Apr;12(4):267-87. doi: 10.1111/j.1463-1326.2009.01175.x. Review.

PMID:
20380648
[PubMed - indexed for MEDLINE]
8.

The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes.

Hoerger TJ, Ahmann AJ.

J Manag Care Pharm. 2008 Feb;14(1 Suppl C):S2-14; quiz 15-6. Review.

PMID:
18240890
[PubMed - indexed for MEDLINE]
Free Article
9.

Type II diabetes mellitus.

Edelman SV.

Adv Intern Med. 1998;43:449-500. Review.

PMID:
9506190
[PubMed - indexed for MEDLINE]
10.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
[PubMed - indexed for MEDLINE]
11.

Endothelial dysfunction and its role in diabetic vascular disease.

Hartge MM, Kintscher U, Unger T.

Endocrinol Metab Clin North Am. 2006 Sep;35(3):551-60, viii-ix. Review.

PMID:
16959585
[PubMed - indexed for MEDLINE]
12.

Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus.

Guerci B, Böhme P, Kearney-Schwartz A, Zannad F, Drouin P.

Diabetes Metab. 2001 Sep;27(4 Pt 1):436-47. Review.

PMID:
11547217
[PubMed - indexed for MEDLINE]
Free Article
13.

Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Woodman RJ, Chew GT, Watts GF.

Drugs. 2005;65(1):31-74. Review.

PMID:
15610050
[PubMed - indexed for MEDLINE]
14.

Impact of glucagon-like peptide-1 on endothelial function.

Sjöholm A.

Diabetes Obes Metab. 2009 Dec;11 Suppl 3:19-25. doi: 10.1111/j.1463-1326.2009.01074.x. Review.

PMID:
19878258
[PubMed - indexed for MEDLINE]
15.

Treatment strategy for type 2 diabetes from the perspective of systemic vascular protection and insulin resistance.

Utsunomiya K.

Vasc Health Risk Manag. 2012;8:429-36. doi: 10.2147/VHRM.S32357. Epub 2012 Jul 4. Review.

PMID:
22910731
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes.

Cariou B.

Diabetes Metab. 2012 Oct;38(4):298-308. doi: 10.1016/j.diabet.2012.04.003. Epub 2012 Jun 4. Review.

PMID:
22672960
[PubMed - indexed for MEDLINE]
Free Article
17.

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.

Vergès B, Bonnard C, Renard E.

Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25. Review.

PMID:
21871831
[PubMed - indexed for MEDLINE]
Free Article
18.

Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide.

Kitasato L, Tojo T, Hatakeyama Y, Kameda R, Hashikata T, Yamaoka-Tojo M.

Cardiovasc Diabetol. 2012 Jun 29;11:79. doi: 10.1186/1475-2840-11-79. Review.

PMID:
22748110
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.

Campbell RK.

Clin Ther. 2011 May;33(5):511-27. doi: 10.1016/j.clinthera.2011.04.015. Review.

PMID:
21665040
[PubMed - indexed for MEDLINE]
20.

[Vascular dysfunction in metabolic disorders: evaluation of some therapeutic interventions].

Bouskela E, Kraemer de Aguiar LG, Nivoit P, Bahia LR, Villela NR, Bottino DA.

Bull Acad Natl Med. 2007 Mar;191(3):475-92; discussion 492-3. French.

PMID:
18072649
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk